Survival of cancer patients in Navarra and comparison with Spain
DOI:
https://doi.org/10.23938/ASSN.1042Keywords:
Cancer, Survival, Prognosis, Trends, Cancer RegistryAbstract
Background. To analyze the survival of adult cancer patients in Navarre, describe its trend, and compare the data for this Spanish Autonomous Community against that reported for Spain.
Methods. Records of adult cancer patients were retrieved from the Navarre´s population-based cancer registry for two periods (1999-2007 and 2008-2016). The vital status had been updated to 2020. Observed survival, net survival and age-standardized net survival at five years with 95% confidence intervals were estimated overall and for twenty-nine cancer groups.
Results. We analyzed 57,564 cases. Age-standardized net survival was 59.9% (59.1-60.8) and 63.8% (62.8-64.7) for males and females diagnosed with cancer during the 2008-2016 period, respectively. Age-standardized net survival ranged from 13.4% (10.4-17.4) for pancreatic cancer to 94.0% (88.1-100) for thyroid cancer in male patients, and from 11.9% (7.2-19.7) for liver cancer to 95.6% (92.6-98.6-%) for thyroid cancer in female patients. Compared with cases diagnosed in the 1999-2007 period, age-standardized net survival increased in 10 cancer groups, resulting in an overall increase of 5.1 (4.1-6.0) percentage points. The age-standardized net survival in Navarre was 2.7 (1.9-3.4) percentage points higher than that described for Spain for the 2008-2013 period.
Conclusions. In Navarre, the survival of cancer patients diagnosed during the 2008-2016 period improved significantly in comparison to the 1999-2007 period. Different factors may explain this improvement, including earlier diagnoses, more effective treatment options, and better healthcare processes. Overall, survival was higher in women than in men. Our results suggest a higher survival rate in Navarre than in Spain.
Downloads
References
Memoria 2021 del Instituto de Salud Pública y Laboral de Navarra. 2022. Consultada el 27 de enero de 2023. http://www.navarra.es/NR/rdonlyres/75366057-0BD9-45A2-916F-61AC731CFA93/481833/MemoriaISPLNpublicarWeb.pdf
Instituto Nacional de Estadística. Estadística de defunciones según causa de muerte. España. 2020. Consultada el 27 de enero de 2023. https://www.ine.es/
Departamento de Salud. Gobierno de Navarra. Evaluación del Plan de Salud de Navarra 2001-2005. Consultada el 27 de enero de 2023. http://www.navarra.es/NR/rdonlyres/DE11A293-1F71-4AEA-A0AF-08E2D525F76E/146351/EvaluacindelPlandeSalud20012006.pdf
Plan de Salud de Navarra 2006-2012. An Sist Sanit Navar 2007; 30( Suppl 3): 419-458. https://doi.org/10.4321/s1137-66272007000500010
Departamento de Salud. Gobierno de Navarra. Plan de Salud de Navarra 2014-2020. Consultada el 27 de enero de 2023. http://www.navarra.es/appsext/DescargarFichero/default.aspx?codigoAcceso=PortalDeSalud&fichero=Plan de Salud%5CPlan salud 2014-2020 con DL.pdf
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391(10125): 1023-1075, https://doi.org/10.1016/S0140-6736(17)33326-3
DE ANGELIS R, SANT M, COLEMAN MP, FRANCISCI S, BAILI P, PIERANNUNZIO D et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol 2014; 15(1): 23-34. https://doi.org/10.1016/s1470-2045(13)70546-1
ARNOLD M, RUTHERFORD MJ, BARDOT A, FERLAY J, ANDERSSON TML, MYKLEBUST TÅ et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 2019; 20(11): 1493-1505. https://doi.org/10.1016/S1470-2045(19)30456-5
CHIRLAQUE MD, SALMERON D, ARDANAZ E, GALCERAN J, MARTINEZ R, MARCOS-GRAGERA R et al. Cancer survival in Spain: estimate for nine major cancers. Ann Oncol 2010; 21(Suppl 3): iii21-iii29. https://doi.org/10.1093/annonc/mdq082
RODRÍGUEZ-BARRANCO M, SALAMANCA-FERNÁNDEZ E, FAJARDO ML, BAYO E, CHANG-CHAN YL, EXPÓSITO J et al. Patient, tumor, and healthcare factors associated with regional variability in lung cancer survival: a Spanish high-resolution population-based study. Clin Transl Oncol 2019; 21(5): 621-629. https://doi.org/10.1007/s12094-018-1962-9
GUEVARA M, MOLINUEVO A, SALMERÓN D, MARCOS-GRAGERA R, CARULLA M, CHIRLAQUE M-D et al. Cancer survival in adults in Spain: a population-based study of the spanish network of cancer registries (REDECAN). Cancers 2022; 14(10): 2441. https://doi.org/10.3390/cancers14102441
BRAY F, COLOMBET M, MERY L, PIÑEROS M, ZNAOR A, ZANETTI R et al. Cancer Incidence in Five Continents, Vol. XI. IARC Scientific Publication No. 166. 1a ed. Lyon: International Agency for Reasearch on Cancer, 2021.
FRITZ A, PERCY C, JACK A, SHANMUGARATNAM K, SOBIN L, PARKIN DM et al. International Classification of Diseases for Oncology (ICD-O). 3ª ed. Geneva: World Health Organization, 2013.
SWERDLOW SH, CAMPO E, HARRIS NL, JAFFE ES, PILERI SA, STEIN H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer, 2017.
HAEMACARE Working Group. Manual for coding and reporting haematological malignancies. Tumori 2010; 96(4): i-A32. https://www.ncri.ie/sites/ncri/files/pubs/papers/HAEMACAREWorkingGroup2010_ManualforCodingandReportingHaematologialMalignancies.pdf
BRAY F, PARKIN DM. Evaluation of data quality in the cancer registry: Principles and methods. Part I: Comparability, validity and timeliness. Eur J Cancer 2009; 45(5): 747-755. https://doi.org/10.1016/j.ejca.2008.11.032
PERME MP, STARE J, ESTÈVE J. On Estimation in Relative Survival. Biometrics 2012; 68(1): 113-120. https://doi.org/10.1111/j.1541-0420.2011.01640.x
ELANDT-JOHNSON RC, JOHNSON NL. Survival Models and Data Analysis. New York: John Wiley and Sons, 1980.
SWAMINATHAN R, BRENNER H. Stastistical methods for cancer survival analysis. En: Cancer Survival in Africa, Asia, the Caribbean and Central America. Lyon: IARC Publications, 2011; 7-13.
CORAZZIARI I, QUINN M, CAPOCACCIA R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40(15): 2307-2316. https://doi.org/10.1016/j.ejca.2004.07.002
GREENWOOD M. The natural duration of cancer. En: Reports on Public Health and Medical Subjects. Londres: Great Britain Ministry of Health, 1926; 1-26.
PARKIN DM, HAKULINEN T. Analysis of survival. En: Jensen OM, Parkin DM, MacLennan R, Muir C, Skeet RG, editores. Cancer registration: principles and methods. Lyon: IARC, 1991; 159-176. https://publications.iarc.fr/_publications/media/download/3524/70eabd5b1ba64c6974e1f9140668721a07ccb05c.pdf
GUEVARA M, BURGUI R, DÍAZ-GONZÁLEZ J, SALGADO E, VICENTE F, MORENO-IRIBAS C et al. Care patterns and changes in treatment for nonmetastatic breast cancer in 2013–2014 versus 2005: a population-based high-resolution study. Eur J Cancer Prev 2017; 26: S215-S222. https://doi.org/10.1097/CEJ.0000000000000379
GUEVARA M, RODRÍGUEZ-BARRANCO M, PUIGDEMONT M, MINICOZZI P, YANGUAS-BAYONA I, PORRAS-POVEDANO M et al. Disparities in the management of cutaneous malignant melanoma. A population-based high-resolution study. Eur J Cancer Care 2019; 28(4): e13043. https://doi.org/10.1111/ecc.13043
BOSCH F, DALLA-FAVERA R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol 2019; 16(11): 684-701. https://doi.org/10.1038/s41571-019-0239-8
CHIRLAQUE MD, SALMERON D, GALCERAN J, AMEIJIDE A, MATEOS A, TORRELLA A et al. Cancer survival in adult patients in Spain. Results from nine population-based cancer registries. Clin Transl Oncol 2018; 20(2): 201-211. https://doi.org/10.1007/s12094-017-1710-6
HOFFMANN VS, BACCARANI M, HASFORD J, CASTAGNETTI F, DI RAIMONDO F, CASADO LF et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia 2017; 31(3): 593-601. https://doi.org/10.1038/leu.2016.246
BEYNON RA, LANG S, SCHIMANSKY S, PENFOLD CM, WAYLEN A, THOMAS SJ et al. Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all-cause mortality: Results from head and neck 5000, a prospective observational cohort of people with head and neck cancer. Int J Cancer 2018; 143(5): 1114-1127. https://doi.org/10.1002/ijc.31416
GATTA G, BOTTA L, SÁNCHEZ MJ, ANDERSON LA, PIERANNUNZIO D, LICITRA L et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer 2015; 51: 2130-2143. https://doi.org/10.1016/j.ejca.2015.07.043
JONES GS, BALDWIN DR. Recent advances in the management of lung cancer. Clin Med 2018; 18(Suppl 2): s41-s46. https://doi.org/10.7861/clinmedicine.18-2-s41
ROJO ÁLVARO J, BERMEJO FRAILE B, MENÉNDEZ TORRE E, ARDANAZ E, GUEVARA M, ANDA APIÑÁNIZ E. Aumento de la incidencia de cáncer de tiroides en Navarra. Evolución y características clínicas, 1986-2010. Endocrinol Diabetes y Nutr 2017; 64(6): 303-309. https://doi.org/10.1016/j.endinu.2017.02.013
BOSSARD N, VELTEN M, REMONTET L, BELOT A, MAAROUF N, BOUVIER AM et al. Survival of cancer patients in France: A population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007; 43(1): 149-160. https://doi.org/10.1016/j.ejca.2006.07.021
SIEGEL RL, MILLER KD, FUCHS HE, JEMAL A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72(1): 7-33. https://doi.org/10.3322/caac.21708
BAILI P, DI SALVO F, MARCOS-GRAGERA R, SIESLING S, MALLONE S, SANTAQUILANI M et al. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study. Eur J Cancer 2015; 51(15): 2120-2129. https://doi.org/10.1016/J.EJCA.2015.07.025
ELLISON LF. Differences in cancer survival in Canada by sex. Health Reports 2016; 27(4): 19-27. https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2016004/article/14491-eng.pdf?st=DouBunE4
MICHELI A, CIAMPICHINI R, OBERAIGNER W, CICCOLALLO L, DE VRIES E, IZARZUGAZA I et al. The advantage of women in cancer survival: An analysis of EUROCARE-4 data. Eur J Cancer 2009; 45(6): 1017-1027. https://doi.org/10.1016/j.ejca.2008.11.008
GUIZARD AV, UHRY Z, DE RAUCOURT D, MAZZOLENI G, SÁNCHEZ MJ, LIGIER K et al. Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev 2017; 26: S16-S23. https://doi.org/10.1097/CEJ.0000000000000296
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
